A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kβ Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer.

Debashis SarkerNancy A DawsonAna M AparicioTanya B DorffAllan J PantuckUlka N VaishampayanLynn HensonLakshmi VasistSumita Roy-GhantaMichele GorczycaWhitney YorkGopinath GanjiJerry TolsonJohann S de Bono

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Although there was acceptable safety and tolerability with GSK2636771 plus enzalutamide in patients with PTEN-deficient mCRPC after failing enzalutamide, limited antitumor activity was observed.

Keyphrases

prostate cancer
open label
pi k akt
signaling pathway
clinical trial
cell proliferation
phase ii
phase iii
study protocol
phase ii study
radiation therapy
double blind
rectal cancer